Alvotech vs Krystal Biotech
ALVO and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALVO and KRYS compare
Krystal Biotech grew revenue faster over the last twelve months (26.0% versus 19.7% for Alvotech).
Krystal Biotech scores higher on the StockData Score (11 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALVO | KRYS |
|---|---|---|
| Size and price | ||
| Market cap | – | $9.0B |
| Share price | $4.19 | $305.23 |
| Change, 1 year | −25.2% | 50.3% |
| Change, 5 years | −57.8% | 483% |
| Beta (5Y) | 0.43 | 0.84 |
| Employees | 1,000 | 295 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 41.4× |
| P/S | – | 19.2× |
| P/B | – | 6.3× |
| EV/EBITDA | – | 35.7× |
| P/FCF | – | 29.1× |
| FCF yield | – | 3.4% |
| Fair value | – | $214.74 |
| Margin of safety | – | −42.1% |
| Growth | ||
| Revenue growth (TTM) | 19.7% | 26.0% (better) |
| Revenue growth, 5Y average | 54.5% | – |
| Net income growth (TTM) | – | 13.2% |
| EPS growth (TTM) | – | 10.5% |
| Profitability | ||
| Gross margin | 59.8% | – |
| Operating margin | 13.3% | 48.4% (better) |
| Net margin | – | 47.9% |
| FCF margin | −19.6% | 66.0% (better) |
| Return on equity | – | 17.5% |
| Return on invested capital | – | 42.6% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 10.02 | – |
| Interest coverage | 0.5× | – |
| Current ratio | 1.65 | 7.89 (better) |
| Altman Z-score | – | 37.71 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 102% |
| Held by insiders | 67.7% | 17.2% |
| Insider net buying, 12 months | – | −$105M |
| Short interest, % of float | – | 12.4% |
Go deeper
- ALVO stock overview
- ALVO income statement
- ALVO valuation and score
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.